Draft:Oswald Vander Veken Prize

  • Comment: I concur with Mgp28's assessment; I'm unfortunately not seeing enough coverage in reliable sources that are WP:Independent to the awards or award winners.
    We'd need to see significant coverage that's not from FWO/FRS, or from the award winners (and their institutions). Nil🥝 03:04, 13 December 2025 (UTC)
  • Comment: PPS on my previous comment -- if there are references that demonstrate notability that are not in English, you can use those. Mgp28 (talk) 15:36, 7 December 2025 (UTC)
  • Comment: I'm not going to decline this a second time, but despite what has clearly been a lot of effort, this article still doesn't seem to demonstrate that the prize is notable under Wikipedia's notability guideline. There needs to be significant independent discussion of the prize. It is not enough that the prize winners are notable or the organisation awarding it has written about it. One of your edit summaries in September commented "to my knowledge there is nothing more available in verifiable public domain in English". I suggest that this means you aren't going to be able to demonstrate notability for this subject.
    Also, your user name matches the name of one of the prize recipients. This could be interpreted as a conflict of interest. I suggest you look at WP:COI and consider disclosing any conflict.
    PS - I recommend not deleting comments from previous reviewers as it is a lot easier to understand the draft's history if we can see what people have previously said. Mgp28 (talk) 15:34, 7 December 2025 (UTC)

The Oswald Vander Veken Prize is a European Medicine Prize awarded by the Research Foundation – Flanders (FWO)[1][2] and the Fonds de la Recherche Scientifique-FNRS (F.R.S.-FNRS) every three years since 1987 to acknowledge an original contribution to knowledge about the tumours of the locomotor system (bone tumour and soft tissue tumours), their aetiology, prevention, diagnosis and/or treatment [3]. FWO and F.R.S.-FNRS attach great importance to the promotion of research into the knowledge of tumours [4]. These tumours belong to the category of rare cancers [5] and are sometimes part of hereditary cancer predisposition syndromes [6]. Next to difficulties with diagnosis, real progress in survival is lacking due to limited progress in the design of therapeutic strategies. These patients have unmet supportive care needs [7]. Trans European collaborative networks exist, such as the EGAN network and RARECARENet, to advance care for these rare cancers in Europe [8] [9]. The prize recognizes research with significant impact in the field, potentially influencing future studies or clinical practices. The award, consisting of a diploma and a stipend of 25.000 Euros for personal use, is given to a researcher or a research team of a maximum of three researchers affiliated with a university in the European Economic Area or Switzerland.

The prize is named after a patient who died because of a rare malignant tumour of the skeleton. As a remembrance of him, his family started this prize [10]. The prize is intended to highlight this type of unusual cancer, as despite all research on these tumours, the prognosis of these patients is not very good [11]. It is the only European prize in this area of study (see list of medicine awards). It is considered a prestigious award for this type of research by its triennial nature, the substantial monetary reward, the association with respected organizations like F.R.S.-FNRS and FWO, the international character and the prestige of the previous winners, which come from diverse European countries such as France, Great Britain, the Netherlands, Sweden, Italy and Belgium. Scientific areas of the award-winning proposals include molecular tumour (cyto-)genetics, diagnostic histopathology, experimental treatments, both surgical as well as pharmaceutical, and target identification for potential drug treatments.

Winners

Previous winners include:

  • Claude CAREL, Centre Universitaire de Dijon, University of Burgundy (F) (1987): "Anomalies chromosomiques spécifiques dans des tumeurs solides des tissus mous."[12]
  • Christopher D. M. Fletcher, (St Thomas' Hospital; London (GB) (1990): "Etude des tumeurs des tissus mous au moyen de techniques clinico-pathologiques et biologiques moléculaires et développement d'un sarcome des tissus mous à des fins de diagnostic et de traitement."[13]
  • Gilles Thomas, Directeur de Recherches du C.N.R.S., Curie Institute, Paris (F) (1993): "Clonage des points de cassure de la translocation chromosomique t(11;22) du sarcome d'Ewing, identification des genes impliques et elucidation des consequences structurales de leurs rearrangements."[14]
  • Colin Cooper, Institute of Cancer Research, Surrey (GB) (1996): "Molecular analysis of the t(x;18) and t(9;22) sarcoma translocations: determination of the normal functions of the SYT, SSX1, SSX2 and CHN proteins and appraisal of their use in the management of synovial sarcomas and chondrosarcomas."[15]
  • Alexander M.M. EGGERMONT, Erasmus Universiteit, Rotterdam (NL) (2002): "TNF-based isolated limb perfusion for limb salvage for locally advanced extremity soft tissue sarcomas, and other irresectable tumours."[16]
  • Nils MANDAHL, Fredrik MERTENS, and Ioannis PANAGOPOULOS, Lund University Hospital (SE) (2005): "Cytogenetic and molecular genetic investigation of bone and soft tissue tumours."[17]
  • Pancras C.W. HOGENDOORN, Universiteit Leiden (NL) (2008): "Molecular tumour pathology of tumours of the musculoskeletal system esp. Cartilaginous Tumours."[18]
  • Katia SCOTLANDI, Istituto Ortopedico Rizzoli di Bologna (Italy) (2011): "Development of new bullets against Ewing's sarcoma: academy builds its own industry."[19]
  • Patrick SCHÖFFSKI, KU Leuven (B) 2014: "Activity of Eribulin mesylate in patients with soft tissue sarcoma: a phase II study in four independent histological subtypes (and related work)."[20]
  • Dominique HEYMANN, University of Nantes (F) (2017): "The heterogeneity of the tumour microenvironment as a source of therapeutic targets in bone sarcomas."[21]
  • Anabelle DECOTTIGNIES, UCLouvain (B) (2020): "The ALTernative mechanism of telomere maintenance: a promising target for tumours of the locomotor apparatus?"[22]
  • Thomas SCHUBERT, Robin EVRARD and Pierre-Louis DOCQUIER, UCLouvain (B) (2023): "Improving bone sarcoma surgery."[23]

See Also

List of medicine awards

List of biomedical science awards

References

  1. ^ "Home - FWO".
  2. ^ "Scientific prizes - FWO".
  3. ^ https://www.frs-fnrs.be/docs/Prix/FRS-FNRS_Prix_Oswald_Vander_Veken_EN.pdf [bare URL PDF]
  4. ^ "Fwo".
  5. ^ "Rare Cancers, Cancer Subtypes, and Pre-Cancers".
  6. ^ JE Garber, K Offit. Hereditary cancer predisposition syndromes. J Clin Oncol. 2005;23:276-92
  7. ^ E de Heus, JM van der Zwan, O Husson, AR Frissen, CML van Herpen, MAW Merkx, SFA Duijts. Unmet supportive care needs of patients with rare cancer: A systematic review. Eur J Cancer Care (Engl) 2021;30:e13502
  8. ^ "RARECARENet: Advancing Care for Rare Cancers Across Europe".
  9. ^ https://egan.eu [bare URL]
  10. ^ FWO jaarboek 2010;36-37
  11. ^ "Cancer of the Bones and Joints - Cancer Stat Facts". SEER.
  12. ^ A.A. Sandberg, C. Turc-Carel: The cytogenetics of solid tumors. Relation to diagnosis, classification and pathology. Cancer 1987; 59:387-95
  13. ^ CD Fletcher. Soft tissue tumors. J Pathol 1989 Dec;159:341-4
  14. ^ L Selleri, M Giovannini, A Romo, J Zucman, O Delattre, G Thomas, G A Evans. Cloning of the entire FLI1 gene, disrupted by the Ewing's sarcoma translocation breakpoint on 11q24, in a yeast artificial chromosome Cytogenet Cell Genet 1994;67:129-36
  15. ^ C S Cooper. Translocations in solid tumours. Curr Opin Genet Dev 1996;6:71-5
  16. ^ R van Horssen, T L M Ten Hagen, A M M Eggermont TNF-alpha in cancer treatment: molecular insights, antitumor effects, and clinical utility. Oncologist 2006; 11:397-408
  17. ^ F Mertens, I Panagopoulos, N Mandahl. Genomic characteristics of soft tissue sarcomas.Virchows Arch 2010;456:129-39
  18. ^ J V M G Bovée, P C W Hogendoorn, J S Wunder, B A Alman. Cartilage tumours and bone development: molecular pathology and possible therapeutic targets. Nat Rev Cancer 2010;10:481-8
  19. ^ C Garofalo, M C Manara, G Nicoletti, M T Marino, P-L Lollini, A Astolfi, G Pandini, J A López-Guerrero, K-L Schaefer, A Belfiore, P Picci, K Scotlandi Efficacy of and resistance to anti-IGF-1R therapies in Ewing's sarcoma is dependent on insulin receptor signaling Oncogene 2011;30:2730-40
  20. ^ P Schöffski, IL Ray-Coquard, A Cioffi, N Bin Bui, S Bauer, JT Hartmann, A Krarup-Hansen, V Grünwald, R Sciot, H Dumez, J-Y Blay, A Le Cesne, J Wanders, C Hayward, S Marreaud, M Ouali, P Hohenberger. Activity of eribulin mesylate in patients with soft-tissue sarcoma: a phase 2 study in four independent histological subtypes Lancet Oncol 2011;12:1045-52
  21. ^ M-F Heymann, F Lézot, D Heymann. The contribution of immune infiltrates and the local microenvironment in the pathogenesis of osteosarcoma Cell Immunol. 2019:343:103711
  22. ^ "FNRS rewards research carried out at the Institute". 2 July 2020.
  23. ^ "FNRS.awards : The team of Thomas Schubert, Robin Evrard and Pierre-Louis Docquier (UCLouvain), laureates of the Oswald Vander Veken Prize 2023".
allikas: http://en.wikipedia.org/wiki/Draft:Oswald_Vander_Veken_Prize